These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29857775)

  • 21. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
    Bezzio C; Fascì-Spurio F; Viganò C; Meucci G; Papi C; Saibeni S
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):33-41. PubMed ID: 27805459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the effectiveness of Budesonide MMX
    Jesionowski M; Rydzewska G; Danese S; Paridaens K
    Prz Gastroenterol; 2023; 18(2):154-160. PubMed ID: 37538282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide for the treatment of ulcerative colitis.
    Abdalla MI; Herfarth H
    Expert Opin Pharmacother; 2016 Aug; 17(11):1549-59. PubMed ID: 27157244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
    Löfberg R; Ostergaard Thomsen O; Langholz E; Schiöler R; Danielsson A; Suhr O; Graffner H; Påhlman L; Matzen P; Møller-Petersen JF
    Aliment Pharmacol Ther; 1994 Dec; 8(6):623-9. PubMed ID: 7696452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
    J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
    Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
    J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
    Rubin DT; Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Sale ME; Rolleri RL; Golden PL; Barrett AC; Bortey E; Forbes WP
    Dig Dis Sci; 2015 Nov; 60(11):3408-17. PubMed ID: 26386854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
    Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
    Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
    Cross RK
    Inflamm Bowel Dis; 2017 Oct; 23(10):1689-1701. PubMed ID: 28906290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.